JNJ vs. CPRX

Last updated Jun 13, 2026

JNJ (Johnson & Johnson) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — JNJ in Drug Manufacturers - General, CPRX in Biotechnology. Over the past 10 years, JNJ returned 10.46%/yr vs 46.26%/yr for CPRX. At a 0.13 correlation, their price movements are largely independent.

Performance

JNJ vs. CPRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Johnson & Johnson (JNJ) and Catalyst Pharmaceuticals, Inc. (CPRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, JNJ achieves a 17.68% return, which is significantly lower than CPRX's 34.36% return. Over the past 10 years, JNJ has underperformed CPRX with an annualized return of 10.46%, while CPRX has yielded a comparatively higher 46.26% annualized return.

JNJ

• 1D: 1.07%
• 1M: 5.14%
• YTD: 17.68%
• 6M: 15.11%
• 1Y: 57.60%
• 3Y*: 17.82%
• 5Y*: 10.94%
• 10Y*: 10.46%

CPRX

• 1D: -0.03%
• 1M: 0.64%
• YTD: 34.36%
• 6M: 32.77%
• 1Y: 29.11%
• 3Y*: 39.03%
• 5Y*: 40.44%
• 10Y*: 46.26%

*Multi-year figures are annualized to reflect compound growth (CAGR)

JNJ vs. CPRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
JNJ Johnson & Johnson	17.68%	47.48%	-4.81%	-8.58%	5.97%	11.44%	10.82%	16.22%	-5.13%	24.43%
CPRX Catalyst Pharmaceuticals, Inc.	34.36%	11.84%	24.15%	-9.62%	174.74%	102.69%	-10.93%	95.31%	-50.90%	272.38%

Correlation

The correlation between JNJ and CPRX is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.11
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.15
Correlation (10Y) Calculated over the trailing 10-year period	0.15
Correlation (All Time) Calculated using the full available price history since Nov 8, 2006	0.13

Fundamentals

Market Cap JNJ : $588.98B CPRX : $3.98B
EPS JNJ : $8.65 CPRX : $1.74
PE Ratio JNJ : 27.85 CPRX : 18.02
PEG Ratio JNJ : 0.93 CPRX : 0.32
PS Ratio JNJ : 6.08 CPRX : 6.68
PB Ratio JNJ : 7.25 CPRX : 3.93
Total Revenue (TTM) JNJ : $96.36B CPRX : $596.96M
Gross Profit (TTM) JNJ : $66.60B CPRX : $378.23M
EBITDA (TTM) JNJ : $31.62B CPRX : $313.50M

Return for Risk

JNJ vs. CPRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JNJ

JNJ Risk / Return Rank: 96
JNJ Sharpe Ratio Rank: 97
JNJ Sortino Ratio Rank: 98
JNJ Omega Ratio Rank: 97
JNJ Calmar Ratio Rank: 93
JNJ Martin Ratio Rank: 94

CPRX

CPRX Risk / Return Rank: 69
CPRX Sharpe Ratio Rank: 71
CPRX Sortino Ratio Rank: 66
CPRX Omega Ratio Rank: 66
CPRX Calmar Ratio Rank: 71
CPRX Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JNJ vs. CPRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Johnson & Johnson (JNJ) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	JNJ	CPRX	Difference
Sharpe ratio: Return per unit of total volatility	3.42	0.89	+2.53
Sortino ratio: Return per unit of downside risk	4.94	1.40	+3.54
Omega ratio: Gain probability vs. loss probability	1.61	1.18	+0.43
Calmar ratio: Return relative to maximum drawdown	5.28	1.52	+3.76
Martin ratio: Return relative to average drawdown	15.52	3.46	+12.07

JNJ vs. CPRX - Sharpe Ratio Comparison

The current JNJ Sharpe Ratio is 3.42, which is higher than the CPRX Sharpe Ratio of 0.89. The chart below compares the historical Sharpe Ratios of JNJ and CPRX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

JNJ vs. CPRX - Drawdown Comparison

The maximum JNJ drawdown since its inception was -50.67%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for JNJ and CPRX.

Drawdown Indicators

	JNJ	CPRX	Difference
Max Drawdown Largest peak-to-trough decline	-50.67%	-94.25%	+43.58%
Max Drawdown (1Y) Largest decline over 1 year	-10.96%	-19.18%	+8.22%
Max Drawdown (3Y) Largest decline over 3 years	-15.95%	-27.29%	+11.34%
Max Drawdown (5Y) Largest decline over 5 years	-18.41%	-45.37%	+26.96%
Max Drawdown (10Y) Largest decline over 10 years	-27.37%	-64.87%	+37.50%
Current Drawdown Current decline from peak	-2.54%	-0.03%	-2.51%
Average Drawdown Average peak-to-trough decline	-11.90%	-51.96%	+40.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.72%	9.84%	-6.12%

Volatility

JNJ vs. CPRX - Volatility Comparison

Johnson & Johnson (JNJ) has a higher volatility of 5.47% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 0.47%. This indicates that JNJ's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JNJ	CPRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.47%	0.47%	+5.00%
Volatility (6M) Calculated over the trailing 6-month period	12.16%	23.17%	-11.01%
Volatility (1Y) Calculated over the trailing 1-year period	16.94%	33.28%	-16.34%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.87%	47.77%	-30.90%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.48%	60.39%	-41.91%

Dividends

JNJ vs. CPRX - Dividend Comparison

JNJ's dividend yield for the trailing twelve months is around 2.18%, while CPRX has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CPRX Catalyst Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
JNJ Johnson & Johnson	2.18%	2.48%	3.40%	3.00%	2.52%	2.45%	2.53%	2.57%	2.74%	2.38%	2.73%	2.87%

Financials

JNJ vs. CPRX - Profitability Comparison

The chart below illustrates the profitability comparison between Johnson & Johnson and Catalyst Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a gross profit of 17.20B and revenue of 24.06B. Therefore, the gross margin over that period was 71.5%.

CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported an operating income of 6.40B and revenue of 24.06B, resulting in an operating margin of 26.6%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a net income of 5.24B and revenue of 24.06B, resulting in a net margin of 21.8%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

Frequently Asked Questions

Can I hold both JNJ and CPRX in my portfolio?

JNJ and CPRX have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, JNJ or CPRX?

JNJ has higher volatility (5.47%) compared to CPRX (0.47%). In terms of maximum drawdown, JNJ dropped -50.67% vs CPRX's -94.25%.

Which has better risk-adjusted returns?

JNJ currently has the higher Sharpe Ratio (3.42 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.